Recordati : Back in the rare diseases game in 2019?
>2018 results in line with expectations - Recordati reported its preliminary FY 2018 results midday yesterday. Contract fulfilled for management which reported figures in line with and even slightly better than guidance. The reported figures are in line with our expectations and those of the consensus: sales of € 1,352m (+5%), EBITDA of € 499m (+10%), EBIT of € 442m (+9%) and net profit of € 312m (+8%). Net debt reached € 588m, up € 200m (€ 382m at end-December 2017) ...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.